• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

129.38 +0.72 (+0.56%)
Official Closing Price Updated: 7:00 PM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,584,603
Open 127.64
Bid (Size) 128.28 (100)
Ask (Size) 129.00 (100)
Prev. Close 128.66
Today's Range 126.74 - 129.97
52wk Range 76.66 - 129.97
Shares Outstanding 2,531,374,696
Dividend Yield 2.63%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
June 29, 2026
From Merck & Co., Inc.
Via Business Wire
Explore the top gainers and losers within the dow jones index in today's session. ↗
June 26, 2026
Via Chartmill

Performance

YTD
+21.5%
+21.5%
1 Month
+12.3%
+12.3%
3 Month
+9.6%
+9.6%
6 Month
+21.3%
+21.3%
1 Year
+63.4%
+63.4%

More News

Read More
Stay informed with the top movers within the dow jones index on Thursday. ↗
June 25, 2026
Via Chartmill
What's going on in today's session: dow jones movers ↗
June 25, 2026
Via Chartmill
News headline image
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
June 25, 2026
From Merck & Co., Inc.
Via Business Wire
Wednesday's session: top gainers and losers in the dow jones index ↗
June 24, 2026
Via Chartmill
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
June 24, 2026
Via Investor Brand Network
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
June 24, 2026
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
June 24, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
June 24, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
From BioMedWire
Via GlobeNewswire
Uncover the latest developments among dow jones stocks in today's session. ↗
June 23, 2026
Via Chartmill
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
June 24, 2026
From BioMedWire
Via GlobeNewswire
Exploring the top movers within the dow jones index during today's session. ↗
June 23, 2026
Via Chartmill
Which dow jones stocks are moving on Monday? ↗
June 22, 2026
Via Chartmill
Top dow jones movers in Monday's session ↗
June 22, 2026
Via Chartmill
News headline image
Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
June 22, 2026
From Merck & Co., Inc.
Via Business Wire
Stay informed with the top movers within the dow jones index on Thursday. ↗
June 18, 2026
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
June 18, 2026
Via Chartmill
News headline image
U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
June 18, 2026
From Merck & Co., Inc.
Via Business Wire
Explore the top gainers and losers within the dow jones index in today's session. ↗
June 17, 2026
Via Chartmill
News headline image
Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages
June 17, 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Dividend Stocks to Hold for the Long Haul ↗
June 16, 2026
Via The Motley Fool
Topics Intellectual Property
Discover which dow jones stocks are making waves on Monday. ↗
June 15, 2026
Via Chartmill

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 129.38
When was Merck & Co last traded?
The last trade of Merck & Co was at 06/29/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 327.51B
How many shares of Merck & Co are outstanding?
Merck & Co has 328B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap